Strattera and Wellbutrin: Taking Them Together, Interaction and Differences

Strattera (atomoxetine) and Wellbutrin (bupropion) can be taken together, and sometimes are, especially for adults with ADHD and depression. But there’s an important interaction.

• The interaction: bupropion strongly blocks CYP2D6, the liver enzyme that clears atomoxetine. In a pharmacokinetic study, adding bupropion raised atomoxetine exposure about 5-fold.
• What that means for dosing: on the combination, atomoxetine is started low and raised more slowly. The label recommends waiting 4 weeks before increasing.
• What to watch: heart rate, blood pressure, sleep, anxiety and appetite are monitored closely, because both drugs raise norepinephrine activity.
• Seizure risk: bupropion’s dose limits matter, because it can lower the seizure threshold.
• Separately: Strattera is an FDA-approved non-stimulant for ADHD. Wellbutrin is an antidepressant (also used for smoking cessation) with modest, off-label evidence for adult ADHD.

This is general information, not medical advice. Only combine these medicines under your prescriber’s supervision.

Strattera vs Wellbutrin at a glance

	Strattera (atomoxetine)	Wellbutrin (bupropion)
Main use	ADHD (ages 6+ and adults)	Depression, seasonal affective disorder, smoking cessation (as Zyban)
ADHD status	FDA-approved	Off-label; modest evidence in adults
How it works	Blocks norepinephrine reuptake	Blocks norepinephrine and dopamine reuptake
Controlled substance	No	No
Usual adult dose	40 mg, increasing to 80 mg (max 100 mg)	SR 150 mg twice daily or XL 150 to 300 mg once daily (max 450 mg/day for XL)
Time to work	Weeks (full effect often 4 to 6+ weeks)	Weeks (2 to 6 weeks for mood)
Key risks	Liver injury (rare), suicidal thoughts in young people, heart rate and blood pressure rises, urinary and sexual effects	Seizures (dose-related), insomnia, anxiety, blood pressure rise, suicidal thoughts in young people
Sexual side effects	Possible (erectile problems in adults)	Low; sometimes used to counter SSRI sexual side effects
Generic	Yes	Yes

Can you take Strattera and Wellbutrin together?

Yes, under medical supervision. Prescribers sometimes combine them for:

• Adults with both ADHD and depression, where bupropion treats the depression and atomoxetine treats the ADHD.
• People who want or need to avoid stimulants (substance misuse history, heart concerns, stimulant side effects), using two non-controlled medicines.
• Partial response to one drug, where the other is added.
• Smokers with ADHD who are trying to quit, since bupropion helps with smoking cessation.

There isn’t a large randomized trial of the combination specifically for ADHD, so it’s based on the pharmacology and clinical experience rather than direct trial evidence. Its safety depends on handling the interaction properly.

The Strattera and Wellbutrin interaction explained

Atomoxetine is broken down almost entirely by the liver enzyme CYP2D6. Bupropion and its main metabolite are strong inhibitors of CYP2D6. When they’re combined, atomoxetine clears much more slowly and builds up to higher levels.

• In a study in healthy volunteers, a week of bupropion 300 mg/day raised atomoxetine’s total exposure about 5-fold (AUC up from about 1,580 to 8,060 ng·h/mL) and prolonged its half-life.
• That’s similar to what happens in people who are genetically CYP2D6 “poor metabolizers”, about 7% of white people.
• The pharmacogenetics guideline for atomoxetine (CPIC) names bupropion, along with fluoxetine and paroxetine, as a strong CYP2D6 inhibitor that can effectively turn a normal metabolizer into a poor one (“phenoconversion”).

Higher atomoxetine levels mean more side effects: faster heart rate, higher blood pressure, insomnia or sleepiness, nausea, dry mouth, reduced appetite, urinary hesitancy and sexual side effects. The Strattera label’s advice for people taking a strong CYP2D6 inhibitor is to start at the usual starting dose (0.5 mg/kg/day in children under 70 kg, or 40 mg/day in adults) and only increase after 4 weeks if symptoms haven’t improved and the dose is well tolerated. Many people on bupropion do well on a lower atomoxetine dose than usual.

The interaction runs mainly one way: atomoxetine doesn’t significantly raise bupropion levels. Bupropion’s own seizure risk still has to be respected, and both drugs add to norepinephrine-related effects on heart rate and blood pressure.

Safety checks on the combination

• Blood pressure and heart rate at baseline and at follow-ups, especially after dose changes.
• Seizure risk: bupropion is contraindicated in people with seizure disorders, current or past bulimia or anorexia, and during abrupt withdrawal from alcohol, benzodiazepines or anti-seizure drugs. Its maximum doses (450 mg/day for XL) shouldn’t be exceeded.
• Mood and suicidal thoughts: both carry boxed warnings for young people. Watch for agitation, worsening depression or unusual behaviour.
• Mania: both can trigger mania in people with bipolar disorder, so screening is needed before starting.
• Liver: stop atomoxetine and seek care for jaundice, dark urine or right upper abdominal pain.
• Sleep and anxiety: both can cause insomnia or jitteriness. Taking bupropion in the morning helps.
• Other CYP2D6 drugs: bupropion also raises levels of some beta-blockers (metoprolol), antidepressants, antipsychotics and codeine-type painkillers (and reduces codeine’s effect).

How each works for ADHD

Atomoxetine selectively blocks norepinephrine reuptake. In the prefrontal cortex it also indirectly raises dopamine, improving attention and impulse control without the reward-pathway effects that make stimulants habit-forming. It’s FDA-approved for ADHD in children 6 and older and adults, and has many placebo-controlled trials behind it.

Bupropion blocks reuptake of both norepinephrine and dopamine, a profile similar in direction to stimulants but much weaker. It isn’t FDA-approved for ADHD. A 2017 Cochrane review of six trials in adults (438 participants) found low-quality evidence that bupropion modestly reduces ADHD symptom severity and increases the chance of clinical improvement, with tolerability similar to placebo. A 2025 Lancet Psychiatry network meta-analysis of adult ADHD treatments also found bupropion more effective than placebo on self-reported symptoms. Overall it’s considered a second- or third-line option for adult ADHD, particularly useful when depression or smoking coexists.

Strattera vs Wellbutrin: which is better for ADHD?

For ADHD alone, atomoxetine has stronger evidence and an FDA approval, while bupropion’s evidence is more limited and mostly in adults. But “which is better” depends on what else is going on:

Situation	Often favours
ADHD in a child or teen	Strattera (approved; bupropion isn’t)
Adult ADHD without depression	Strattera, or a stimulant first
Adult ADHD plus depression	Either, or both. Bupropion treats depression; atomoxetine treats ADHD
Smoker who wants to quit	Bupropion
Sexual side effects are a concern	Bupropion
Anxiety is prominent	Atomoxetine (less likely to worsen anxiety)
Seizure history or eating disorder	Atomoxetine (bupropion is contraindicated)
Liver disease	Bupropion, with caution and dose limits
Want to avoid controlled substances	Either

Dosing

	Strattera	Wellbutrin
Adult starting dose	40 mg/day	SR: 150 mg once daily, then twice daily. XL: 150 mg once daily
Usual target	80 mg/day (once or split)	SR 150 mg twice daily; XL 300 mg once daily
Maximum	100 mg/day	SR 400 mg/day; XL 450 mg/day
When combined	Start 40 mg (or 0.5 mg/kg); increase only after 4 weeks if needed	Usual dosing; keep within maximums
Timing	Morning, or morning and late afternoon; with food if nausea	Morning (and early afternoon for SR) to reduce insomnia

Side effects compared

• Both: dry mouth, nausea, reduced appetite, insomnia, headache, faster heart rate, higher blood pressure, sweating.
• More with atomoxetine: sleepiness or fatigue, stomach ache, erectile problems and urinary hesitancy in adults, rare liver injury.
• More with bupropion: agitation, tremor, anxiety, insomnia, and dose-related seizures (about 0.1% at 300 mg/day and higher at larger doses for the SR form, according to its label). Weight is usually stable or slightly reduced.

Switching from Wellbutrin to Strattera (or back)

When bupropion is stopped, its CYP2D6 inhibition wears off over one to two weeks. If you’re switching from bupropion to atomoxetine, the atomoxetine dose that was right while on bupropion may become too low afterwards, and your prescriber may increase it. Going the other way, adding or switching to bupropion while on atomoxetine, can cause atomoxetine levels to rise sharply over the following week or two, so the atomoxetine dose may need lowering. Neither drug should be stopped abruptly if you’re taking it for depression. Bupropion is usually tapered, and atomoxetine can be stopped without tapering per its label, but symptoms may return.

What to expect when starting the combination

Time	What’s typical
First 1 to 2 weeks	Side effects appear first: dry mouth, reduced appetite, nausea, sleep changes, a faster pulse. If bupropion is the newer drug, atomoxetine levels are still climbing over this period.
Weeks 2 to 4	Mood effects of bupropion often begin. Atomoxetine’s focus benefits build gradually.
Week 4 review	Prescriber checks blood pressure, heart rate, mood and side effects, and decides whether atomoxetine needs increasing.
Weeks 6 to 12	Fuller effect of both medicines. Further dose adjustments are made slowly.

People’s experience of the combination varies widely. Some find two non-stimulants together give steady, all-day symptom control with improved mood. Others find the side effects, particularly insomnia, appetite loss or a racing heart, too much at standard doses. That’s why slow, monitored dose changes matter more here than with either drug alone.

Monitoring checklist

Check	When
Blood pressure and heart rate	Before starting, after each dose change, then periodically
Mood, sleep, anxiety, suicidal thoughts	Every visit, especially in the first months and in under-25s
Weight and appetite (and height in children)	Each visit
Liver symptoms	Ongoing awareness; tests if symptoms appear
Seizure risk factors	Before starting bupropion and if circumstances change (alcohol, eating disorder, head injury)
Other medicines	Each time a new drug is added, given bupropion’s CYP2D6 effects

Should you get CYP2D6 genetic testing?

The current Strattera label suggests considering genetic testing to determine a patient’s CYP2D6 metabolizer status, and the CPIC pharmacogenetics guideline gives genotype-based dosing advice. Testing can be useful if someone has unusually strong side effects at low atomoxetine doses, or no response at standard doses. But when you take bupropion, your genotype matters less, because bupropion’s inhibition can make even a normal metabolizer behave like a poor one. In that situation, clinical response and side effects guide the dose more than the test does.

Children and teens

Atomoxetine is approved for ADHD from age 6. Bupropion isn’t approved for ADHD or depression in children and teens in the US, though specialists occasionally use it off-label. Both carry boxed warnings about suicidal thoughts in young people. Combining them in a child or adolescent is uncommon and is usually done only by a child and adolescent psychiatrist, with close monitoring of mood, blood pressure, growth and sleep.

Pregnancy and breastfeeding

Bupropion has a reasonable amount of pregnancy data and is sometimes continued when needed for depression or smoking cessation. Atomoxetine has limited human pregnancy data. If you’re planning a pregnancy, review both medicines with your prescriber in advance. The decision weighs the risks of untreated depression and ADHD against the limited data. Both pass into breast milk, and bupropion has rarely been linked to seizures in breastfed infants.

Alcohol and other cautions

Alcohol should be minimized with bupropion. Heavy drinking and sudden alcohol withdrawal both raise seizure risk. Atomoxetine’s liver warning is another reason to limit alcohol. Check our alcohol and medication interaction checker and our guide to Wellbutrin and alcohol. Avoid MAO inhibitors with both, and tell your prescriber about every medicine, including over-the-counter decongestants and supplements.

See also Concerta vs Strattera, Qelbree vs Strattera, Buspirone vs Wellbutrin and our ADHD medication comparison tool.

Frequently asked questions

Can you take Strattera and Wellbutrin together?

Yes, under supervision. Bupropion raises atomoxetine levels about 5-fold by blocking CYP2D6, so atomoxetine is started low and increased slowly, with heart rate, blood pressure and side effects monitored.

Is Wellbutrin approved for ADHD?

No. It’s used off-label. A Cochrane review found low-quality evidence of a modest benefit in adults. Strattera is FDA-approved for ADHD.

Which is better for ADHD, Strattera or Wellbutrin?

Strattera has stronger evidence and approval for ADHD. Wellbutrin can make sense for adults with ADHD and depression, or those quitting smoking, sometimes combined with Strattera.

What are the risks of combining them?

Higher atomoxetine levels, with more side effects such as fast heart rate, raised blood pressure, insomnia and nausea. There’s also bupropion’s dose-related seizure risk, and the boxed warnings for suicidal thoughts in young people.

How do you switch from Wellbutrin to Strattera?

Usually by tapering bupropion while starting atomoxetine. Once bupropion is gone, atomoxetine levels fall, so the dose may need increasing. Follow your prescriber’s plan.

References

• Strattera (atomoxetine) prescribing information. Eli Lilly, 2026.
• Wellbutrin (bupropion) prescribing information. DailyMed.
• Evaluation of a potential metabolism-mediated drug-drug interaction between atomoxetine and bupropion in healthy volunteers.
• Verbeeck W, et al. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2017.
• Brown JT, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther. 2019.
• Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults. Lancet Psychiatry. 2025.